Who owns PRECIGEN, INC. (PGEN)? Elite investor 13F holders
2 tracked elite investors reported holding PRECIGEN, INC as of 2026-06-30, including Patient Capital Management, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Patient Capital Management | PRECIGEN INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 108510760.00 USD | 19036976.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | PRECIGEN INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 3450210.00 USD | 605300.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.